Pulse Biosciences Business Updates and Q1 2026 Financial Results
Pulse Biosciences, Inc. has announced business updates and financial results for the first quarter of 2026, highlighting the strategic prioritization of its nPulse Cardiac Catheter System following promising clinical data presented at the AF Symposium.
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the first quarter ended March 31, 2026. Recent Business Highlights Endocardial Catheter AF Ablation Announced strategic prioritization of the nPulse Cardiac Catheter System following landmark clinical data, presented at AF Symposium, demonst